Advertisement

Neurological Sciences

, Volume 35, Issue 7, pp 1109–1114 | Cite as

Predictors of outcome of myasthenic crisis

  • J. KalitaEmail author
  • A. K. Kohat
  • U. K. Misra
Original Article

Abstract

There is paucity of study on predictors of myasthenic crisis (MC), prolonged ventilation and their outcome, a reason why this study was undertaken. Sixty-four patients with myasthenia gravis (MG) were included whose median age was 45 (6–84) years. Their clinical treatment, presence of thymoma, anti-acetylcholine receptor antibody (AchRAb), thymectomy, comorbidities, offending drugs and occurrence of MC were noted. Patients needing prolonged ventilation (>15 days) were noted. Hospital mortality, MG quality of life (QOL) at discharge and thereafter annual hospital visit, admission, expenditure and work day loss were enquired. Fourteen (21.9 %) patients had MC within 1–120 (median 8.5) months of disease onset within a median follow-up of 48 (3–264) months. The precipitating factors were infection in six, surgery in five, tapering of drugs in two and reaction to iodinated contrast in one patient. Male gender, bulbar weakness, AchRAb, thymoma, surgery and comorbid illnesses were related to MC. Eight of them (57.1 %) needed prolonged ventilation. Half the patients with MC had recurrent crisis (2–4 attacks). Death was not related to MC although MC patients had worse QOL, higher annual treatment expenditure with frequent hospital visit and hospitalization. In conclusion, association of comorbid illness with MC and prolonged ventilation highlights the need of close follow-up and appropriate management.

Keywords

Myasthenia gravis Myasthenic crisis Outcome Infection Quality of life Economics loss Prolonged ventilation AchR antibody 

Notes

Acknowledgments

We thank Rakesh Kumar Nigam and Deepak Kumar Anand for secretarial help. Funding support none.

Conflict of interest

There is no conflict of interest to declare.

References

  1. 1.
    Cohen MS, Younger D (1981) Aspects of the natural history of myasthenia gravis: crisis and death. Ann NY Acad Sci 377:670–677PubMedCrossRefGoogle Scholar
  2. 2.
    Phillips LH 2nd (2003) The epidemiology of myasthenia gravis. Ann NY Acad Sci 998:407–412PubMedCrossRefGoogle Scholar
  3. 3.
    Fink ME (1993) Treatment of the critically ill patient with myasthenia gravis. In: Ropper AH (ed) Neurological and neurosurgical intensive care, 3rd edn. Raven Press, New York, pp 351–362Google Scholar
  4. 4.
    Bedlack RS, Sanders DB (2002) On the concept of myasthenic crisis. J Clin Neuromuscul Dis 4:40–42PubMedCrossRefGoogle Scholar
  5. 5.
    Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, Brannagan TH, Fink ME, Rowland LP (1997) Myasthenic crisis clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48:1253–1260PubMedCrossRefGoogle Scholar
  6. 6.
    Aggarwal AN, Gupta D, Behera D, Prabhakar S, Jindal SK (2002) Intensive respiratory care in patients with myasthenic crisis. Neurol India 50:348–351PubMedGoogle Scholar
  7. 7.
    Panda S, Goyal V, Behari M, Singh S, Srivastava T (2004) Myasthenic crisis: a retrospective study. Neurol India 52:453–456PubMedGoogle Scholar
  8. 8.
    Narayan SK, Sarada C, Radhakrishnan K, Nair MD, Kartha CC, Neelakandhan KS, Tharakan KJ (1996) Response to thymectomy in south Indian patients with myasthenia gravis. Acta Neurol Scand 94:63–66PubMedCrossRefGoogle Scholar
  9. 9.
    Osserman KE, Genkins G (1971) Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med 38:497–537PubMedGoogle Scholar
  10. 10.
    Burns TM, Conaway, Cutter GR, Sanders DB, Muscle Study Group (2008) Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 38:957–963PubMedCrossRefGoogle Scholar
  11. 11.
    Juel VC (2004) Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 24:75–81PubMedCrossRefGoogle Scholar
  12. 12.
    Meena AK, Prasad VS, Murthy JM (2001) Neurological intensive care in India—disease spectrum and outcome. Neurol India 49 Suppl 1:1–7Google Scholar
  13. 13.
    Murthy JM, Meena AK, Chowdary GV, Naryanan JT (2005) Myasthenic crisis: clinical features, complications and mortality. Neurol India 53:37–40PubMedCrossRefGoogle Scholar
  14. 14.
    Chaudhuri A, Behan PO (2009) Myasthenic crisis. QJM 102:97–107PubMedCrossRefGoogle Scholar
  15. 15.
    Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48:1246–1252PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Lennon VA (1997) Serologic profile of myasthenia gravis and distinction from the Lambert–Eaton myasthenic syndrome. Neurology 48:23SCrossRefGoogle Scholar
  17. 17.
    López-Cano M, Ponseti Bosch JM, Espin Basany E, Sánchez García JL, Armengol Carrasco M (2003) Predictors of survival in patients with myasthenia gravis and thymoma. Med Clin (Barc) 120:401–404CrossRefGoogle Scholar
  18. 18.
    Roy A, Kalita J, Misra UK, Kar D, Agarwal A, Misra SK (2000) A study of myasthenia gravis in patients with and without thymoma. Neurol India 48:343–346PubMedGoogle Scholar
  19. 19.
    Werneck LC, Scola RH, Germiniani FM, Comerlato EA, Cunha FM (2002) Myasthenic crisis: report of 24 cases. Arq Neuropsiquiatr 60:519–526PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.Department of NeurologySanjay Gandhi Post Graduate Institute of Medical SciencesLucknowIndia

Personalised recommendations